Diligence memo · auto-generated · as of July 2, 2026
Agile Sciences, Inc
Agile Sciences, Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Agile Sciences, Inc operates in Pharmaceuticals, based in Raleigh.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Agile Sciences, Inc has raised $2.3M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.3M on 2007-11-02.
Most recent recorded round closed around 2020-05-18.
Valuation (modeled)modeled
Provath models Agile Sciences, Inc at approximately $38M (range $756K–$298M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.67× the median modeled value of Seed Pharmaceuticals companies in 2019–2021 (49 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 151 months.
Last raise 6.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 30% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 38% of those peers.
Closest niche peers: Wiesman Capital & Co., LLC, Curzion Pharmaceuticals, Inc., Providence Therapeutics Inc., EnBiotix, Inc., Metuchen Pharmaceuticals, LLC.
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.